CD4 and neoplasm: Based on this, authors recently demonstrated in NSG mice that CD4+ CD26hi CAR-T cells mediate durable and relapse-free immunity while bulk CD4+, Th1, Th2 or Th17 cell therapies elicited only transient delays in human tumor growth.